Webinars & Podcasts

"Immunopathogenic and Clinical Considerations in the Early Diagnosis and Management of Bronchiolitis Obliterans Syndrome”, CHEST 2022 Learning Theater, Sponsored by Zambon USA Ltd., is available here.

The webinar “Looking into the “I”s of NCFB” is available here.

“A Deep Dive into the “I”s of Non-cystic fibrosis bronchiectasis” webinar is available here.

“The Future of Bronchiolitis Obliterans Syndrome” podcast sponsored by Zambon USA Ltd is available on ISHLT Voices here.

Events

Lung Transplant Foundation
Virtual Meeting on BOS

The Lung Transplant Foundation held an externally-led patient-focused drug development meeting on Bronchiolitis Obliterans Syndrome. For additional information and to view a replay of the meeting, visit here.

• Zambon Announces New Data Highlighting Lifetime Burden of Illness in U.S. Patients with Bronchiolitis Obliterans Syndrome at ISPOR 2023
  Download press release

• Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)
  Download press release

• October 14, 2022 - Zambon Announces Attendance at CHEST Annual Meeting 2022
  Download press release
• May 12, 2022 - Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
  Download press release
• April 26, 2022 - Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022
  Download press release
• April 21, 2022 - Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
  Download press release
• September 8, 2021 - Positive Results from Phase 3 PROMIS-I Study of CMS I-neb^® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
  Read more
• April 29, 2021 - Key data on economic impact of BOS presented at ISHLT 2021
  Download press release